A Real-world Study of Inetetamab for First-line Treatment of MBC

Not yet recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Breast CancerReal-world Study

Interventions

DRUG

Inetetamab

Inetetamab-based treatment for first-line treatment of HER2-positive MBC

All Listed Sponsors

collaborator

Hunan Medical University General Hospital

UNKNOWN

lead

Hunan Cancer Hospital

OTHER

NCT05980208 - A Real-world Study of Inetetamab for First-line Treatment of MBC | Biotech Hunter | Biotech Hunter